Абстрактный

Anaphylactic Reaction After Initial Exposure to Basiliximab

Fragale Guillermo*, Lovisolo Patricia , Beitía Vanina and Martin Rodolfo

Balisiliximab is a widely used monoclonal antibody in renal transplant for immunosuppression induction. Its introduction has decreased the incidence in acute rejection during the first year after renal transplantation; however it does not show any long-term benefits. Case presentation: A 38 year old patient who suffers from a severe anaphylactic reaction after initial exposure to Basiliximab before kidney transplantation which led to his death.